Development and delivery of innovative pharmaceutical products for respiratory, neonatology, transplantation, and rare diseases.
B
CSR Analysis score
The organization is among the top 20% of most committed organizations, excluding the top 5%, among comparable organizations.
+160,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: May 2026
Evaluation in progress...
This analysis is not yet available in English. Please see the French version.
Leading organizations
Sanofi
B
Development of innovative medicines and vaccines, focusing on therapeutic areas like rare diseases, neurology, immunology, oncology, diabetes, cardiovascular diseases, and consumer healthcare.
Orphan Europe
B
Development and commercialization of drugs for rare diseases.
AstraZeneca
B
Research, development, production, and marketing of prescription drugs in four therapeutic areas: cardiovascular, renal & metabolism, oncology, respiratory & immunology, and rare diseases.
Initiatives identified among leaders
Programmes de santé pour les communautés vulnérables
“Sanofi Pasteur met en place des programmes de sant...” - SanofiRéduction des émissions de gaz à effet de serre
“AstraZeneca vise à réduire les émissions de gaz à ...” - AstraZenecaSoutenir les communautés locales
“Orphan Europe soutient les communautés locales, en...” - Orphan Europe64% of similar organizations communicate on CSR issues
+1832 initiatives collected from 50 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports